AP Biosciences advances next-generation bispecific antibody therapies for solid tumor immunotherapy

2025-09-22 / GlobalBio & Investment

APBiosciences,Inc.isadvancingnext-generationCD137bispecificantibodytherapiesforsolidtumorimmunotherapy. AttheTaiwanImmuno-OncologyDrugDevelopmentForum,founderDr.JengHersharedhowAPBiosciencesisdifferen...

GBIHighlights Oncology mRNA Immunotherapy

Elixiron Targets T-Cell Exhaustion with Next-Gen Cancer Immunotherapies

2025-09-18 / GlobalBio & Investment

On16thSeptember,Dr.Hung-KaiChen,Founder&CEOofElixironImmunotherapeutics,sharedthecompany’sinnovativepipelineaddressingoneofthetoughestchallengesinoncology—TcellexhaustionattheTaiwanImm...

GBIHighlights ICI Immunotherapy Oncology

GNT Biotech Advances GNTbm-38 with IND Filings in US & China by 2026

2025-09-18 / GlobalBio & Investment

GNTBiotech&MedicalsCorporation(GNTbm)isadvancingGNTbm-38,anext-generationoralimmuno-regulatorydrug,withINDfilingsplannedintheUS&Chinabyearly2026.InvestmentHighlightsGlobalIPStrength:38inventio...

GBIHighlights 6926 Exosome ESCO Oncology

Shine-On Bio Licenses Exosome Drug Tech to ESCO Aster for NT$200M

2025-09-16 / GlobalBio & Investment

Shine-OnBio(StockCode:6926.TWO)hassignedalicensingagreementworthoverNT$200MwithSingapore’sleadingbiopharmacompanyESCOAster(EA),grantingrightstoitspatentedexosome-basedsmallmoleculedrug-loadingte...